The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 17, 2020

Filed:

Jun. 27, 2017
Applicant:

University of Washington, Seattle, WA (US);

Inventors:

Brandon J. Ausk, Seattle, WA (US);

Steven Bain, Seattle, WA (US);

Ted S. Gross, Seattle, WA (US);

Assignee:

UNIVERSITY OF WASHINGTON, Seattle, WA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61M 5/32 (2006.01); A61M 5/42 (2006.01); A61B 17/34 (2006.01); A61M 5/00 (2006.01); A61M 5/19 (2006.01); A61M 5/20 (2006.01); A61M 5/315 (2006.01); A61M 5/46 (2006.01); A61B 17/20 (2006.01);
U.S. Cl.
CPC ...
A61M 5/3297 (2013.01); A61B 17/3403 (2013.01); A61M 5/007 (2013.01); A61M 5/19 (2013.01); A61M 5/20 (2013.01); A61M 5/31596 (2013.01); A61M 5/427 (2013.01); A61M 5/46 (2013.01); A61B 17/205 (2013.01); A61B 2017/3411 (2013.01); A61M 5/3287 (2013.01); A61M 5/3295 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); A61M 2205/52 (2013.01);
Abstract

Methods of protecting muscle tissue from heterotopic ossification employ targeted deliveries of a neuromuscular inhibitor. A method of protecting muscle tissue from heterotopic ossification includes identifying a volume of muscle tissue that is susceptible to heterotopic ossification. A first aliquot of a therapeutic dose of a neuromuscular inhibitor is delivered at a first delivery site within the volume of muscle tissue. A second aliquot of the therapeutic dose is delivered at a second delivery site within the volume of muscle tissue. The first and second delivery sites are separated by a distance to distribute the therapeutic dose within the targeted volume of muscle tissue.


Find Patent Forward Citations

Loading…